IGC Pharma, Inc.IGCNYSE
Loading
Year-over-year net income growth rate
Percentile
P44
Within normal range
vs 5Y Ago
-1.2x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | -13.88% |
| Q2 2025 | -33.58% |
| Q1 2025 | 34.55% |
| Q4 2024 | -6.52% |
| Q3 2024 | 27.80% |
| Q2 2024 | 17.57% |
| Q1 2024 | 48.38% |
| Q4 2023 | -128.03% |
| Q3 2023 | -18.12% |
| Q2 2023 | 48.51% |
| Q1 2023 | -79.19% |
| Q4 2022 | 7.90% |
| Q3 2022 | 12.32% |
| Q2 2022 | 57.17% |
| Q1 2022 | -173.12% |
| Q4 2021 | 45.19% |
| Q3 2021 | -142.95% |
| Q2 2021 | 39.37% |
| Q1 2021 | -26.95% |
| Q4 2020 | -40.19% |
| Q3 2020 | 11.96% |
| Q2 2020 | 40.33% |
| Q1 2020 | -96.76% |
| Q4 2019 | -35.96% |
| Q3 2019 | 14.50% |
| Q2 2019 | 12.61% |
| Q1 2019 | -37.46% |
| Q4 2018 | -33.80% |
| Q3 2018 | -67.48% |
| Q2 2018 | 10.91% |
| Q1 2018 | -7.96% |
| Q4 2017 | -75.30% |
| Q3 2017 | 29.70% |
| Q2 2017 | 42.91% |
| Q1 2017 | -575.89% |
| Q4 2016 | 80.82% |
| Q3 2016 | -52.08% |
| Q2 2016 | 73.01% |
| Q1 2016 | -253.10% |
| Q4 2015 | 35.31% |